

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medtide Inc.

泰德醫藥(浙江)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3880)

ACCEPTANCE BY THE CSRC OF APPLICATION FOR THE COMPANY'S H SHARE FULL CIRCULATION PLAN

This announcement is made by Medtide Inc. (the **"Company"**) pursuant to Rule 13.09(2)(a) of the Rules (the **"Listing Rules"**) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **"Stock Exchange"**) and the Inside Information Provisions (as defined in the Listing Rules, namely under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

The Company is pleased to announce that the China Securities Regulatory Commission (中國證券監督管理委員會) (the **"CSRC"**) has accepted the Company's application for the proposed implementation of the H share full circulation to the CSRC on behalf of certain shareholders of the Company. Pursuant to the relevant application documents, the Company has applied for the conversion of the 68,201,112 unlisted shares with par value of RMB1.0 per Share in issue held by such shareholders of the Company (the **"Unlisted Shares"**) into H shares with par value of RMB1.0 per Share (the **"H Share Full Circulation"**), which represents approximately 48.10% of the total issued share capital of the Company as at the date of this announcement. Upon obtaining all the relevant approvals (including the filings with and/or approvals from the CSRC and the Stock Exchange) and having complied with all the applicable laws, regulations and rules, such Unlisted Shares will be converted into H Shares, and the Company will apply for the listing of and permission to deal in such H Shares on the main board of the Stock Exchange (the **"Conversion and Listing"**). Pursuant to the articles of association of the Company, no further shareholders' meeting is required to be convened to approve the Conversion and Listing.

Upon completion of the H Share Full Circulation, all shareholders holding Unlisted Shares participating in the H Share Full Circulation will still be required to fulfil the share lock-up undertaking in accordance with the requirements of the Listing Rules and applicable laws and regulations.

As at the date of this announcement, details of the Conversion and Listing have not been finalized. The Company will make further announcement(s) on the progress of the Conversion and Listing in accordance with the requirements of the Listing Rules and applicable laws and regulations.

The H Share Full Circulation, the Conversion and Listing are subject to other relevant procedures as required by the CSRC, the Stock Exchange and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

Medtide Inc.

泰德醫藥(浙江)股份有限公司

Dr. Xu Qi

Chairwoman and Executive Director

Hong Kong, July 27, 2025

As at the date of this announcement, the executive directors of the Company are Dr. Xu Qi, Dr. Li Xiang, Ms. Li Xiangli, Ms. Cheng Tao and Ms. Li Lingmei; the non-executive director of the Company is Mr. Wu Yihui; and the independent non-executive directors of the Company are Dr. Yu Cheung Hoi, Dr. Zhu Xun and Mr. Xia Xinsheng.